Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLTXMoonLake Immunotherapeutics$19.94+2.1%$18.73$5.95▼$62.75$1.47B1.041.53 million shs656,719 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLTXMoonLake Immunotherapeutics-4.36%+1.93%+4.44%+8.32%-61.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLTXMoonLake Immunotherapeutics$19.94+2.1%$18.73$5.95▼$62.75$1.47B1.041.53 million shs656,719 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLTXMoonLake Immunotherapeutics-4.36%+1.93%+4.44%+8.32%-61.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMLTXMoonLake Immunotherapeutics 2.41Hold$24.2121.45% UpsideCurrent Analyst Ratings BreakdownLatest MLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026MLTXMoonLake Immunotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $29.006/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/12/2026MLTXMoonLake Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/12/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.005/11/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)Latest MLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026MLTXMoonLake Immunotherapeutics-$0.91N/AN/AN/AN/AN/A5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMLTXMoonLake Immunotherapeutics0.398.608.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipMLTXMoonLake Immunotherapeutics12.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMLTXMoonLake Immunotherapeutics273.61 million64.74 millionOptionableMLTX HeadlinesRecent News About These CompaniesMoonlake Immunotherapeutics Share Price (MLTX.US)1 hour ago | lse.co.ukMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 68,289 SharesJuly 14 at 4:13 AM | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 33,936 Shares of StockJuly 14 at 4:13 AM | americanbankingnews.comDa Silva Jorge Santos Sells 33,936 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) StockJuly 14 at 4:06 AM | insidertrades.comDa Silva Jorge Santos Sells 33,936 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) StockJuly 13 at 5:06 PM | marketbeat.comDa Silva Jorge Santos Sells 68,289 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) StockJuly 13 at 5:06 PM | marketbeat.comSLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff NearsJuly 12 at 12:04 AM | finance.yahoo.comMoonLake Immunotherapeutics $MLTX Shares Bought by Candriam S.C.A.July 12 at 10:47 AM | marketbeat.comMoonLake Immunotherapeutics Class AJuly 11, 2026 | edition.cnn.comInsider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $956,933.25 in StockJuly 5, 2026 | americanbankingnews.comMoonLake Immunotherapeutics' CFO Sells 39K SharesJuly 3, 2026 | finance.yahoo.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $956,933.25 in StockJuly 3, 2026 | insidertrades.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, Leerink Partners Analyst SaysJuly 1, 2026 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis SuppurativaJune 30, 2026 | finance.yahoo.comMoonLake Immunotherapeutics - Ordinary Shares - Class AJune 26, 2026 | money.usnews.comMoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label ExpansionJune 26, 2026 | seekingalpha.comHow Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On OfferingJune 25, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Announces $200 Million Public OfferingJune 25, 2026 | tipranks.comGuggenheim Remains a Buy on MoonLake Immunotherapeutics (MLTX)June 24, 2026 | theglobeandmail.comWhy MoonLake Immunotherapeutics Stock Wilted on WednesdayJune 24, 2026 | fool.comWhy MoonLake Immunotherapeutics Stock Wilted on WednesdayJune 24, 2026 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLTX Company DescriptionsMoonLake Immunotherapeutics NASDAQ:MLTX$19.94 +0.42 (+2.14%) As of 02:40 PM Eastern This is a fair market value price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s AI Spending Question Looms Over Q2 Earnings 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger 3 Gold Stocks Under $5 With Massive Upside CleanSpark Inks a $6.6B AI Lease to Become a Digital Landlord Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet Blueprint for a Billion: Nebius Group Secures the AI Floor Marriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
